GlassScriptPhysician profile
Nicole Bailey
NPI 1912445651
$5,935.63
in general payments reported to CMS, 2019-2025
29 companies · $493 in 2025
The $493 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $916 · 2022: $1,937 · 2023: $1,256 · 2024: $1,335 · 2025: $493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,083.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $885.60 | 2022-2025 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $712.37 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $517.70 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $499.43 | 2021-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $468.91 | 2022-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $428.43 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $321.99 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.61 | 2021-2023 | Trintellix |
| Davol INC. | $260.46 | 2022 | |
| Lundbeck LLC | $244.09 | 2021-2024 | Rexulti, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $238.39 | 2021-2024 | Caplyta |
| Janssen Pharmaceuticals, INC | $187.60 | 2022-2025 | Spravato |
| Alkermes, INC. | $115.22 | 2022-2024 | Lybalvi, Aristada |
| Indivior INC. | $101.42 | 2021-2024 | Perseris |
| Tris Pharma INC | $96.30 | 2021-2024 | Dyanavel Xr |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $89.50 | 2024-2025 | Ingrezza |
| Ethicon US, LLC | $83.64 | 2024 | Prolene, Dermabond, Stratafix |
| E.R. Squibb & Sons, L.L.C. | $80.52 | 2025 | Cobenfy |
| Biogen, INC. | $60.05 | 2024-2025 | Zurzuvae |
| Axsome Therapeutics, INC. | $59.94 | 2022-2023 | Auvelity |
| Idorsia Pharmaceuticals US INC | $34.72 | 2023 | Quviviq |
| Ironshore Pharmaceuticals INC. | $34.64 | 2022-2024 | |
| Noven Therapeutics, LLC | $32.54 | 2024-2025 | Xelstrym |
| Bausch Health US, LLC | $23.65 | 2022 | |
| Almatica Pharma LLC | $18.76 | 2024 | Loreev Xr |
| Edwards Lifesciences Corporation | $17.39 | 2022 | |
| Zimmer Biomet Holdings, INC. | $16.12 | 2021 | |
| Gilead Sciences, INC. | $15.86 | 2022 | |
| Kyowa Kirin, INC. | $14.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.